We are pleased to announce The Max Foundation CEO and co-founder, Pat Garcia-Gonzalez, has been nominated as one of three finalists for the Outstanding Contribution to Cancer Control Award, by UICC. We are honored to see The Max Foundation’s efforts recognized by the UICC.
Pat Garcia-Gonzalez shared her gratitude, saying, “This nomination means the world to me and to all whose voices we represent. At The Max Foundation we believe that all people should be able to access the treatment they need, geography should not be destiny, and everyone should be able to strive for health with dignity and hope.
In the past 20 years we have demonstrated that it is possible to safely treat many cancers in low- and middle-income countries. Now we can prevent unnecessary suffering and premature death and because we can, we must.”
Pat is nominated in the civil society category, alongside Paul Farmer, Co-Founder and Chief Strategist, Partners in Health, and Maira Caleffi, breast surgeon and founder of FEMAMA. UICC has also nominated President Joe Biden, Minister Greg Hunt, and President Paul Kagame in the policy-makers category.
The panel of judges for UICC’s Outstanding Contribution to Cancer Control Awards includes: the members of the Board of the Union for International Cancer Control (UICC); the Editors in Chief of the three following scientific journals: Lancet Oncology, International Journal of Cancer, Journal of Global Oncology; and the CEO of the American Society for Clinical Pathology.
The Awards Ceremony will take place October 26th at the 2021 World Cancer Leaders’ Summit in Boston.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.
The Max Foundation and Novartis renew their commitment to CML patients
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
